SML2883
Paquinimod
≥98% (HPLC), powder, immunomodulator
别名:
ABR 215757, ABR 25757, ABR-215757, ABR-25757, ABR215757, ABR25757, N,5-二乙基-1,2-二氢-4-羟基-1-甲基-2-氧基-N-苯基-3-喹啉甲酰胺, N-乙基-N-苯基-1,2-二氢-5-乙基-4-羟基-1-甲基-2-羟基喹啉-3-甲酰胺, N-乙基-N-苯基-5-乙基-1,2-二氢-4-羟基-1-甲基-2-羟基喹啉-3-甲酰胺
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C21H22N2O3
化学文摘社编号:
分子量:
350.41
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
产品名称
Paquinimod, ≥98% (HPLC)
SMILES string
N1(c2c(c(ccc2)CC)C(=O)C(C1=O)C(=O)N(CC)c3ccccc3)C
InChI
1S/C21H22N2O3/c1-4-14-10-9-13-16-17(14)19(24)18(20(25)22(16)3)21(26)23(5-2)15-11-7-6-8-12-15/h6-13,18H,4-5H2,1-3H3
InChI key
RBHDLRDFJPBLNO-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
Paquinimod (ABR-215757)是一种口服活性喹啉-3-甲酰胺（Q物质）类免疫调节剂，靶向S100A9（Calgranulin B；MRP14），并阻断其与晚期糖基化终产物受体(RAGE)和Toll样受体4的相互作用（IC50 = 26 μM & 23 μM对100 nM hS100A9， 分别结合固定化hRAGE & hTLR4/MD2）。Paquinimod在自身免疫性/炎症性疾病的小鼠模型中证明了体内疗效，包括肝纤维化、胶原诱导的骨关节炎、腹膜炎、EAE、1型糖尿病、狼疮(0.04-25 mg/kg/day p.o)和动脉粥样硬化(10 mg/kg i.p.)。
口服活性S100A9（Calgranulin B；MRP14）阻滞剂在自身免疫性疾病的小鼠模型中具有体内疗效。
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Sahar Tahvili et al.
PloS one, 13(5), e0196598-e0196598 (2018-05-10)
Quinoline-3-carboxamides (Q compounds) are immunomodulatory compounds that have shown efficacy both in autoimmune disease and cancer. We have in here investigated the impact of one such compound, paquinimod, on the development of diabetes in the NOD mouse model for type
Michael J Kraakman et al.
The Journal of clinical investigation, 127(6), 2133-2147 (2017-05-16)
Platelets play a critical role in atherogenesis and thrombosis-mediated myocardial ischemia, processes that are accelerated in diabetes. Whether hyperglycemia promotes platelet production and whether enhanced platelet production contributes to enhanced atherothrombosis remains unknown. Here we found that in response to
Sofia Helmersson et al.
The American journal of pathology, 182(5), 1671-1680 (2013-03-20)
Quinoline-3-carboxamide compounds (Q compounds) have demonstrated efficacy in treating autoimmune disease in both humans and mice. However, the mode of action of these compounds is poorly understood. Here, we show that preventive treatment with the Q compound paquinimod (ABR-215757) during
Christina Wache et al.
The Journal of infectious diseases, 212(2), 247-257 (2015-01-22)
Neutrophilic inflammation often persists for days despite effective antibiotic treatment and contributes to brain damage in bacterial meningitis. We propose here that myeloid-related protein 14 (MRP14), an abundant cytosolic protein in myeloid cells, acts as an endogenous danger signal, driving
R F Schelbergen et al.
Annals of the rheumatic diseases, 74(12), 2254-2258 (2015-05-15)
Alarmins S100A8/A9 regulate pathology in experimental osteoarthritis (OA). Paquinimod is an immunomodulatory compound preventing S100A9 binding to TLR-4. We investigated the effect of paquinimod on experimental OA and human OA synovium. Two OA mouse models differing in level of synovial
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持